Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

July 31, 2028

Conditions

Platinum-sensitive Ovarian Cancer

Interventions

DRUG

AK112 low dose

10mg/kg, Q3W, ivgtt

DRUG

Chemotherapy

ivgtt

DRUG

Olaparib

bid, oral

DRUG

AK112 high dose

20mg/kg, Q3W, ivgtt

Trial Locations (1)

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan